NKCL Bio Group Inc. announced on
November 25 that it had won the Grand Prize in the ‘Innovation Sector’ award
from the Minister of Small and Medium Venture Business.
The Ministry of SMEs and Startups said,
“NKCL Bio Group was highly evaluated for its contribution to the development of
the Korean bio industry, such as enhancing national competitiveness through
innovative management activities.”
NKCL Bio Group, which won the Minister
of SMEs and Startups Award this year, is a bio company that researches and
develops NK cell treatment, a next-generation anti-cancer treatment using
Natural Killer Cell (NK Cell), which is in charge of the most important immune
system in our body.
NK cell, a natural killer cell that
recognizes and attacks abnormal cells such as cancer cells, as the
Keyword, it improved national
competitiveness and raised the growth potential of the Korean economy.
In addition, by providing a
'personalized immune care platform', it is advancing from the global
immuno-anticancer drug market worth 100 billion dollars to the anti-aging and
beauty market through differentiated technological competitiveness such as
"targeted therapy, NK cell automated culture system, etc." The GMP
automatic culture system incorporating artificial intelligence finds a culture
environment optimized for NK cell culture by itself, reduces dependence on
existing high-quality manpower, and improves production efficiency by more than
NKCL Biogroup has developed further,
from the stage of maximizing cell yield by simply culturing immune cells as in the existing treatment
method, in consideration of the diversity, immunosuppression, and tumor
mutations in the recent cancer expression situation. Officials revealed that
they are reaching the technology that can control the appropriate cell activity
customed to each patient.
In addition, efforts are being made to
establish a more systematic treatment system in the future through the
self-programmed individual immune screening system.
In addition, △various business expansion
through continuous MOU △establishment of overseas corporations (Vietnam, China)
and business promotion △contribution to job creation through continuous sales
growth △contributing to the vitalization of venture businesses through various
activities and boasting a high level of social contribution.
In response, Chairman Shin Dong-hwa
said, “The proportion of NK cell therapy, a next-generation biopharmaceutical,
in the global pharmaceutical and bio market is gradually increasing. With the
completion of the preclinical trials of RK-NKTM cell therapy product, it has
been proven that it can be a treatment that can effectively control cancer
cells," he said. "As a bio company, we apply blockchain technology to
the bio industry, not just bio technology. We will present the data more
credibly,” he added.
Meanwhile, this award is hosted and
sponsored by TV Chosun, Ministry of Science and ICT, Ministry of Trade,
Industry and Energy, Ministry of Health and Welfare, Ministry of Environment,
Ministry of Employment and Labor, Ministry of Gender Equality and Family,
Ministry of SMEs and Startups, Ministry of Food and Drug Safety, and Shared
Growth Committee. As a result of the NKCL Bio Group's focus on innovative
management, it has borne fruit of winning the Minister of SMEs and Startups